MarketPulse

weight-loss drug

12 articles
The Motley FoolThe Motley Fool··Eric Volkman

Eli Lilly's Weight-Loss Drug Stumbles Out of Gate, Stock Drops Nearly 4%

Eli Lilly's new weight-loss drug Foundayo recorded just 3,707 prescriptions in week two, trailing Novo Nordisk's Wegovy by over 400%, triggering a 4% stock decline.
LLYNVOIQVstock declineFDA approval
BenzingaBenzinga··Vandana Singh

Eli Lilly's Oral Weight Loss Drug Clears Cardiovascular Safety Hurdle

Eli Lilly's oral weight loss drug Foundayo met cardiovascular safety goals in Phase 3 trials, showing 57% lower mortality risk versus insulin. FDA filing planned for Q2 2026.
LLYFDA approvalweight-loss drug
The Motley FoolThe Motley Fool··Eric Volkman

Eli Lilly Surges on FDA Approval of Foundayo, Challenging Novo Nordisk's Weight-Loss Dominance

Eli Lilly stock surged 4% after FDA approval of Foundayo, its oral weight-loss pill priced at $149/month, competing with Novo Nordisk's Wegovy.
LLYNVOFDA approvalstock performance
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Pfizer's Comeback Play: GLP-1 Pivot and 6.2% Yield Appeal to Long-Term Investors

Pfizer pursues GLP-1 market opportunity through acquisition after internal failure, offering 6.2% dividend yield amid 50% stock decline from 2021 peaks.
PFELLYNVOdividend yieldGLP-1 drugs
BenzingaBenzinga··Vandana Singh

Novo Nordisk Wins FDA Nod for High-Dose Wegovy, Expanding GLP-1 Arsenal

Novo Nordisk wins FDA approval for Wegovy HD, a higher-dose version launching in April across 70,000+ U.S. pharmacies, despite modest stock decline.
NVOHIMSFDA approvalclinical trial
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Eli Lilly's Oral GLP-1 Drug Could Reshape Weight Loss Market as Novo Nordisk Faces Competition

Eli Lilly's orforglipron oral GLP-1 drug offers no food restrictions and dual obesity-diabetes approval potential, threatening Novo Nordisk's oral Wegovy dominance.
LLYNVOpharmaceutical competitionweight-loss drug
BenzingaBenzinga··Vandana Singh

Hims & Hers Settles Novo Nordisk Patent Dispute, Inks GLP-1 Partnership

Hims & Hers and Novo Nordisk end legal battle, partnering to distribute weight-loss drugs via telehealth. Stock surges 48.67% despite mixed guidance.
NVOHIMSguidance missearnings beat
BenzingaBenzinga··Vandana Singh

Pfizer's Weight-Loss Drug Wins China Approval, Intensifying GLP-1 Competition

Pfizer wins NMPA approval for weight-loss drug ecnoglutide in China, achieving 15.4% average weight loss in trials, intensifying competition as Novo Nordisk's Wegovy faces patent expiry.
PFELLYNVOclinical trialweight-loss drug
BenzingaBenzinga··Vandana Singh

Novo Nordisk's CagriSema Falls Short in Weight-Loss Trial Against Lilly's Tirzepatide

Novo Nordisk's CagriSema underperformed Eli Lilly's tirzepatide in weight-loss trials, delivering 20.2% versus 23.6% weight reduction, triggering stock declines amid intensifying obesity drug competition.
LLYNVOclinical trialtirzepatide
BenzingaBenzinga··Erica Kollmann

Novo Nordisk Stock Drops 16% After CagriSema Misses Efficacy Target

Novo Nordisk's stock fell 16% after CagriSema obesity drug failed to match Eli Lilly's tirzepatide in trial, showing weaker weight loss results and jeopardizing approval timeline.
LLYNVOclinical trialobesity market
BenzingaBenzinga··Vandana Singh

Novo Nordisk Shares Decline on CagriSema Trial Setback Versus Lilly Rival

Novo Nordisk shares plunged 13% after CagriSema obesity drug trial missed non-inferiority target versus Eli Lilly's tirzepatide, threatening competitive positioning.
LLYNVOFDA approvalclinical trial
BenzingaBenzinga··Namrata Sen

Eli Lilly Stockpiles $1.5B in Experimental Weight-Loss Drug Ahead of FDA Review

Eli Lilly stockpiles $1.5B of experimental weight-loss drug orforglipron ahead of expected April FDA approval decision, signaling management confidence.
LLYNVOFDA approvalpharmaceutical competition